key: cord-0871510-x9a3lag8
authors: Testa, C. B.; Godoi, L. G. d.; Bortolotto, M. R. d. F. L.; Monroy, N. A. J.; Mattos, B. R. d.; Rodrigues, A. S.; Francisco, R. P. V.
title: Cardiovascular diseases worsen the maternal prognosis of COVID-19
date: 2022-04-05
journal: nan
DOI: 10.1101/2022.03.31.22273072
sha: d93ae4106b1c17d074882d50e3e4a3a1675b18ed
doc_id: 871510
cord_uid: x9a3lag8

Cardiovascular diseases are a risk factor for severe cases of COVID-19. There are no studies evaluating whether the presence of CVD in pregnant women and in postpartum women with COVID-19 is associated with a worse prognosis. In an anonymized open database of the Ministry of Health, we selected cases of pregnant and postpartum women who were hospitalized due to COVID-19 infection. Among the 1,876,953 reported cases, 3,562 confirmed cases of pregnant and postpartum women were included, of which 602 had CVD. Patients with CVD had an older age (p<0,001), a higher incidence of diabetes (p<0,001) and obesity (p<0,001), a higher frequency of systemic (p<0,001) and respiratory symptoms (p<0,001). CVD was a risk factor for ICU admission (p<0,001), ventilatory support (p=0.004) and orotracheal intubation in the third trimester (OR 1.30 CI95%1.04-1.62). The group CVD had a higher mortality (18.9% vs. 13.5%, p<0,001), with a 32% higher risk of death (OR 1.32 CI95%1.16-1.50). Moreover, the risk was increased in the second (OR 1.94 CI95%1.43-2.63) and third (OR 1.29 CI95%1.04-1.60) trimesters, as well as puerperium (OR 1.27 IC95%1.03-1.56). Hospitalized obstetric patients with CVD and COVID-19 are more symptomatic. Their management demand more ICU admission and ventilatory support and the mortality is higher.

Maternal mortality is one of the most sensitive markers of health care because it has multiple economic and social impacts. Brazil has a maternal mortality rate of 59.1/100,000 live births (1), above the values considered acceptable by the World Health Organization, which established as a millennium goal for Brazil rates below 35/100,000 live births (2) .

The presence of cardiovascular diseases (CVD) is among the main indirect causes of maternal mortality in the world, the Mainly in developed countries of which is found in developed countries (3, 4) . In Brazil, CVD accounted for 7% to 9.6% of maternal deaths in the years 2011 to 2019 (5) .

During the COVID-19 pandemic, maternal mortality has increased significantly in the world. Currently, the postpartum period has been recognized as a risk factor for complications such as infection (6) . By the time this article was written, Brazil had recorded 13,769 cases of Severe Acute Respiratory Syndrome (SARS) and 1,461 deaths (12.3%) due to COVID-19 during the postpartum period (7) .

Studies reported that CVD is an independent risk factor for severe cases of COVID-19 in the general population. However, there are no studies that have evaluated whether the presence of CVD in pregnant and postpartum women with COVID-19 can be considered a risk factor as well for having a poor prognosis. Furthermore, a study implied that there was an increase in the already high mortality rates in this group of women (8).

Since the Influenza A (H1N1) pandemic in 2009, the Brazilian Ministry of Health has since established and maintained the Influenza Epidemiological Surveillance Information System (Sistema de Vigilância Epidemiológica de Gripe, SIVEP-Gripe), with the possibility of access to data without the individual identification of the patient (anonymized data), on an open basis (9, 10) . Thus, according to Brazilian regulations, there is no need for prior approval by institutions board review.

During the COVID-19 pandemic, the notification in the SIVEP-Gripe of cases of patients with SARS hospitalized in all health units in the country has been compulsory. It has enabled the evaluation of diagnosis, demographic and epidemiological data, and the evolution of cases. The case definition of SARS is of an individual with flu-like syndrome with at least two of the following signs and symptoms: fever, chills, sore throat, headache, cough, rhinorrhea, olfactory or taste disorders. They often present with dyspnea/respiratory distress, persistent chest pressure, O2 saturation less than 95% in ambient air, or cyanosis of the lips or face (11) .

We conducted a search in the SIVEP-gripe database on May 5, 2021, on the cases reported in the period between the 8th epidemiological week of 2020 (beginning of the pandemics in Brazil) and the 15th epidemiological week of 2021 (period between February 16, 2020, and April 17, 2021).

We selected cases of SARS with a confirmed diagnosis of COVID-19 who had been hospitalized. After that, we selected pregnant and postpartum women aged 10 to 55 years old with data regarding their CVD status.

The evaluated variables were the date of onset of symptoms, age, ethnic group, education, time of pregnancy, risk factors, reported comorbidities (hemopathy, liver disease, asthma, diabetes, neuropathy, pneumopathy, immunodepression, nephropathy and obesity), symptoms, ICU admission, ventilatory support, orotracheal intubation, and outcomes.

The analyses were performed using the statistical software R (12) . The qualitative variables are presented as absolute frequency (n) and percentage (%), while the quantitative variables are presented as mean ± standard deviation (SD).

There were two groups according to the presence or absence of CVD. The comparison between the groups for categorical variables was performed through the Χ2 test. The correction was conducted by Yates and the Fisher's exact test, when necessary. In addition, the odds ratios (OR) were also calculated with the confidence interval being 95% (95% CI). For continuous variables, the comparison between the independent groups was analyzed by the t-Student test or the Wilcoxon signed-rank test with continuity correction, when appropriate. The results were considered statistically significant when p < 0.05.

To control selection biases in non-experimental studies, the CVD and non-CVD groups were balanced with respect to age, ethnic group, obesity, and the presence of diabetes (potential confounding variables in the study). Propensity score matching (PSM) was used for estimating and assessing balancing weights of the observations to make two balanced groups through Inverse Probability of Treatment Weighting Method (IPTW). Logistic regression was the method used to create the propensity score weights and the Average Treatment Effect (ATE) is estimated for treatment effects based on IPTW. Analyses related to the comparison of symptoms and outcomes in the groups with and without CVD were redone considering the PSM weights. PSM was carried out with the R Weightlt package (13, 14) . The groups were balanced in relation to age, ethnic group, obesity, diabetes, as can be seen in the article documentation (supplementary material).

In the period between the 8th epidemiological week of 2020 and the 15th epidemiological week of 2021 in a consultation held on May 5, 2021, we found 1,876,953 reported cases. We selected only the confirmed and hospitalized cases of COVID-19 in pregnant and postpartum women aged 10 to 55 years who had in their notification the information about the presence or absence of CVD ( Figure 1 ). The final sample size consisted of 3,562 cases, 602 (17%) of which were patients with CVD. We noticed that the absolute numbers were increased in both groups from March to May 2020, with a high level until July. This was when the first wave of the pandemic occurred in Brazil. Furthermore, there was a fall between August and October and a new increase until March 2021, during which the second wave of the pandemic occurred in Brazil. Comparing the growth rates, we noticed that despite presenting similar general trends of growth, in the first wave of the COVID-19 pandemic in Brazil, the group with CVD presented lower growth rates of COVID-19 cases than that of the non-CVD group. This was different from what happened in the 2nd wave in which CVD patients were mostly affected.

The characteristics of the studied population are presented in Table 1 . Patients with CVD were older (34.76 ± 8.52 vs. 30.00 ± 7.43 years, p < 0,001), more often aged over 35 years (49.8% vs. 28.0%, p < 0,001). When we evaluated the presence of comorbidities, patients with CVD disease had a higher percentage of associated diseases (p < 0,001). Furthermore, the prevalence of diabetes (33.6% vs. 11.4%, p<0,001), pneumopathy (3.0% vs. 1.1%, p = 0.002), nephropathy (4.4% vs. 1.2%, p < 0,001), and obesity (23.4% vs. 8.8%, p<0,001) were higher in this group. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. 1.59 CI95% 1.45-1.75) . The presence of at least one respiratory symptom affected 83.7% of this group, while there were only 68.1% without CVD (OR 1.68 95% CI 1.51 -1.88), as well as the presence of a greater number of associated respiratory symptoms that was more frequent in patients with CVD (p<0.001) ( Table 2 and Table 3 ). The presence of CVD was a risk factor for ICU admission (p < 0,001). After PSM evaluation, we found a 22% higher risk of admission in the CVD group (OR 1.22 95% CI 1.10-1.35), and the risk was increased in the first (OR 1.92 CI95%1.17 -3.15) and second (OR 1.34 IC95%1.05-1.71) trimester and in the puerperium period (OR 1.30 IC95% 1.08-1.55). Similarly, we found that patients with CVD more often required ventilatory support, both noninvasive and invasive (p = 0.004). There was a greater need for orotracheal intubation of CVD patients in the third trimester of pregnancy (OR 1.30 95% CI 1.04-1.62). The length of ICU stay was not statistically different after analysis of the groups via PSM (Table 4 ). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. Among the patients evaluated, 3,047 had a positive outcome (cure), while 515 died (14.4%). Mortality was higher in the CVD group (18.9% vs. 13.5%, p < 0,001). As shown in Figure 3 , the percentage of mortality among patients with CVD was higher in virtually all months evaluated, with an increasing trend in the proportion of deaths since August 2020 and stabilization at higher levels in March and April 2021. After balancing by PSM, the group with CVD presented a 32% higher risk of death (OR 1.32 95%CI 1.16-1.50). The distribution by trimesters of pregnancy and puerperium showed a similar risk of death in the first trimester and increased in the second (OR 1.94 95% CI 1.43-2.63) and third (OR 1.29 CI95% 1.04-1.60) trimesters. The same was found in the puerperium group (OR 1.27 CI95% 1.03-1.56) in patients in the CVD group. 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ;  Patients with CVD presented a higher risk of admission to the ICU, need for ventilatory support in all phases of the pregnancy-puerperal cycle studied and orotracheal intubation in the third trimester. In addition, they had a higher mortality rate in the period analyzed, with a 32% higher risk of death than patients without CVD. The evaluation of moment of pregnancy and puerperium cycle showed an increased risk of death in the second and third trimesters and in the puerperium.

In our population data base, among 3,562 cases of pregnant and puerperal women hospitalized with confirmed COVID-19, we found 602 patients with CVD (17%), a higher incidence than that found in population studies with estimates of around 0.2% to 4% of the pregnant women as carriers of CVD (15, 16) . It is noted that the frequency of CVD in our study was similar to that referred to us and in the North American population study with 8,207 pregnant women with a positive laboratory test for COVID-19, in which 14% of the pregnant women had CVD (17) .

The assessment of declared comorbidities showed that patients with CVD had a greater number of associated comorbidities compared to patients without cardiovascular involvement, with a significantly higher incidence of diabetes and obesity, which were used in the Propensity Score Matching (PSM) balancing technique, as well as age and race, to avoid that these factors could impact the results and the comparison between the groups Pregnant women with CVD were more symptomatic compared with the control group. They also had more rates of systemic symptoms, such as fever and cough, and respiratory symptoms, such as dyspnea, respiratory distress, and O2 saturation less than 95%. In a systematic review involving 185 obstetric patients evaluated, Narang et al. found 53.2% of patients presented fever, 33.13% cough, and 13% dyspnea (18) . In our study, the incidence of symptoms was significantly higher, probably because our cohort included only hospitalized patients. In the CVD group, the prevalence of at least one respiratory symptom was 83.7%, with 72.3% of patients presenting with dyspnea, and 56.6% of patients presenting with a saturation drop below 95%. The presence of significantly higher rates of respiratory symptoms in the group of patients with CVD emphasized the importance of adequate clinical diagnosis of complicated COVID-19 infection. Considering that among the main signs and symptoms of cardiac decompensation during pregnancy are cough and respiratory symptoms such as dyspnea, respiratory distress and saturation loss, symptoms among clinical conditions may overlap. In addition, among the main causes of clinical decompensation of a pregnant woman with a pathological cardiac condition is infection (19) (20) (21) (22) .

ICU admission occurred in 29.6% of the cases in our cohort. This is a rate higher than that found by Narang et al. in a meta-analysis (3.24%) (18) and by Zambrano et al. in a population study with patients who tested positive for COVID-19 (10.5%) (23) . It was observed that when only hospitalized patients were evaluated, the percentage of ICU patients was higher. This was supported by a study by Maeda et al., which involved obstetric patients admitted to a reference hospital for the care of pregnant women with COVID-19 (22.9%) (24) . In patients with CVD, admission to the ICU was found in 37% of the cases evaluated. ICU admission indirectly reflected the case with more severe evolution and was directly related to the need for ventilatory support. In our study, patients with CVD required ventilatory support, both noninvasive and invasive, with an orotracheal intubation rate of 19.8%.

In the face of changes imposed by pregnancy, the cardiovascular system undergoes several adaptations that directly impact the management of severe patients and contribute to the higher mortality of these patients (25) . Maternal mortality in patients with CVD is high, with significant variations according to their baseline CVD, which ranges from 1 to 5%. However, this population always have a higher mortality compared with the general population (19, (26) (27) (28) . In the context of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2022. ;  the COVID-19 pandemic, the presence of CVD has been recognized as a risk factor for death in several studies and meta-analyses that considered the general population, with incidence of CVD in 37 to 69% of hospitalized cases and lethality rate of 10.5 to 15.5% (29, 30) . However, there is no study in the literature evaluating mortality in obstetric population with CVD in the presence of COVID-19 infection. In our cohort, mortality among pregnant and puerperal women hospitalized with COVID-19 was 14.4%. In the group of patients with CVD, 18.9% of the patients died. The mortality found was higher than those reported in the literature for the general population, which reinforces our hypothesis that pregnant women have a more severe presentation.

Among the greatest difficulties in assisting patients with CVD, COVID-19 infection is the most common infection that presents with respiratory symptoms, which may be secondary to infection or triggered cardiac decompensation. The high proportion of deaths in this group, sustained throughout the months of the pandemic, demonstrate the difficulty of clinical management especially in those with comorbidities.

In addition, we should consider that the patient with CVD is, in general, a chronic patient. During the pandemic period, in which human and material resources were allocated for the treatment of COVID-19, many patients lost their follow-ups and had treatment delays, which might worsen their primary diseases (31) .

Mortality in this group, therefore, results from a potentially severe infection in patients at increased risk due to puerperal pregnancy status and CVD, associated with the risks of decompensation of the primary disease, treatment failure, and difficulty in accessing health.

To date, only one series of five cases has been published evaluating the association between the presence of CVD and pregnancy in the presence of COVID-19 infection (31) . We were worth a population database, which allows us to study a large number of hospitalized cases and with the outcome finalized (3,562 cases evaluated and 609 patients with CVD). So far, this is the largest number of obstetric patients with CVD studied in the face of COVID-19 infection. Among the limitations of the study, we should consider that the completion of the notification system included information about the presence or absence of CVD in 39.58% of the notifications, with a high percentage of loss. The difficulty in population-based use was also portrayed by other researchers. In the USA, for instance, only 5.8% (7162) of 122653 cases reported to the CDC had information about health conditions (32) . In addition, we found limitation on the type of CV, since the notification form does not allow etiological distinction and interpretation of access to ICU admission in Brazil. This is because only 15% of maternity hospitals in our country have adult ICU beds (33).

Obstetric patients with CVD and COVID-19 who are hospitalized are more symptomatic. They require ICU hospitalization and ventilatory support. Moreover, they have higher mortality rate than COVID-19 patients without CVD. Mortality in this group may be a consequence of the association between the severity of COVID-19 infection in pregnant women associated with the presence of CVD (which are, by themselves, are recognized risk factor for ICU admission, orotracheal intubation, and death during pregnancy and puerperium). Further studies are needed in this group of patients to determine the main associated risk factors, analyze individually the etiology of CVD, and thus allow improvements in care and consequent reduction in maternal mortality rates. Data Availability Statement: Datasets are available in the Kaggle public repository at the URL: https://www.kaggle.com/datasets/agatharodrigues/papermaternal. These data were derived from the following resources available in the public domains: https://opendatasus.saude.gov.br/dataset/bd-srag-2020 and https://opendatasus.saude.gov.br/dataset/bd-srag-2021, obtained on May 5, 2021. All the R code and documentation are available in GitHub repository at https://github.com/observatorioobstetrico/COVID19_CVD.

The authors declare no conflict of interest.

Maio/2020

I Conferência Internacional de Monitoramento dos Objetivos de Desenvolvimento do Milênio no Setor Saúde: Rumo ao Alcance das Metas de

Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer

ESC Guidelines on the management of cardiovascular diseases during pregnancy

Painel de monitoramento de Mortalidade Materna por CID 10

Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Departamento de informática. Open data SUS System

Departamento de. Open data SUS System

R: A language and environment for statistical computing. R Foundation for Statistical Computing

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

WeightIt" Type Package Title Weighting for Covariate Balance in Observational Studies

Cardiac disease in pregnancy

Assessment and evaluation of the woman with cardiac disease during pregnancy

Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review

ESC Guidelines for the management of cardiovascular diseases during pregnancy

Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs

Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study

Pregnancy in patients with heart disease / Cardiopatia e gravidez

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Vertical transmission of SARS-CoV2 during pregnancy: A high-risk cohort

Pregnancy and delivery in cardiac disease

Who Classification As a Risk Predictor in Pregnancy and Heart Disease

Pregnancy in patients with heart disease: experience with 1,000 cases

Pregnancy in women with complex congenital heart disease. A constant challenge

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review

Impact of COVID-19 on pregnant women with Rheumatic heart disease or Peripartum cardiomyopathy

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

COVID-19 and Maternal Death in Brazil: An Invisible Tragedy. Rev Bras Ginecol e Obs / RBGO Gynecol Obstet